Executives
-
Galvin RoyPresident, Global Plasma & BC -
Miller Laurie A.SVP, Human Resources
-
Simon, ChristopherPresident & CEO
-
Strong Stewart WPresident, Global Hospital
-
Lingamneni AnilaEVP, Chief Technology Officer
-
Llorens JosepEVP, Global Manufacturing
-
Basil Michelle LEVP and General Counsel
-
Maunsell Farris MaryanneVP, Chief Accounting Officer
-
Darecca JamesEVP, Chief Financial Officer
?
Simon, Christopher
President & CEO
Haemonetics Corporation
US, Boston [HQ]
CIK
1674993
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
433,877
Price per Share :
$73.49
Equivalence :
$31,885,620.73
Transaction History
-
M433,877 Shares After TransactionValue : $18,066,638.28$4,352,046.24Transaction Date : 06/06/24
-
Footnotes
-
-
Footnotes:#1 Represents an automatic exercise of options granted in 2017 and scheduled to expire after June 6, 2024, as reflected in this Form 4.#2 This number includes unvested restricted stock units previously reported.#3 Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
-
F362,542 Shares After TransactionValue : $31,678,919.96$6,233,252.30Transaction Date : 06/06/24
-
Footnotes
-
-
Footnotes:#1 Represents an automatic exercise of options granted in 2017 and scheduled to expire after June 6, 2024, as reflected in this Form 4.#2 This number includes unvested restricted stock units previously reported.#3 Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
-
F250,411 Shares After TransactionValue : $23,971,845.03$386,462.01Transaction Date : 05/17/24
-
Footnotes
-
-
Footnotes:#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.#2 This number includes unvested RSUs previously reported.#3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.#4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
-
A265,035 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/17/24
-
Footnotes
-
-
Footnotes:#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.#2 This number includes unvested RSUs previously reported.#3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.#4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
-
F256,355 Shares After TransactionValue : $24,735,693.95$142,805.20Transaction Date : 05/15/24
-
Footnotes
-
-
Footnotes:#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.#2 This number includes unvested RSUs previously reported as well as 289 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2024.